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Parainﬂuenza virus
Viral vectorsTo test the potential for parainﬂuenza virus 5 (PIV5)-based vectors to provide protection from vaccinia virus
(VACV) infection, PIV5 was engineered to express secreted VACV L1R and B5R proteins, two important
antigens for neutralization of intracellular mature (IMV) and extracellular enveloped (EEV) virions,
respectively. Protection of mice from lethal intranasal VACV challenge required intranasal immunization
with PIV5-L1R/B5R in a prime-boost protocol, and correlated with low VACV-induced pathology in the
respiratory tract and anti-VACV neutralizing antibody. Mice immunized with PIV5-L1R/B5R showed some
disease symptoms following VACV challenge such as loss of weight and hunching, but these symptoms were
delayed and less severe than with unimmunized control mice. While immunization with PIV5 expressing B5R
alone conferred at least some protection, the most effective immunization included the PIV5 vector
expressing L1R alone or in combination with PIV5-B5R. PIV5-L1R/B5R vectors elicited protection from VACV
challenge even when CD8+ cells were depleted, but not in the case of mice that were defective in B cell
production. Mice were protected from VACV challenge out to at least 1.5 years after immunization with PIV5-
L1R/B5R vectors, and showed signiﬁcant levels of anti-VACV neutralizing antibodies. These results
demonstrate the potential for PIV5-based vectors to provide long lasting protection against complex
human respiratory pathogens such as VACV, but also highlight the need to understand mechanisms for the
generation of strong immune responses against poorly immunogenic viral proteins.logy and Immunology, Wake
d., Winston-Salem, NC 27157-
e Drive, Frederick, MC 21702,
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
The respiratory tract can be a major entry site for many pathogenic
viruses, including inﬂuenza virus, paramyxoviruses, coronaviruses, pox
viruses and herpes viruses. The outcomes of these viral infections can be
signiﬁcantly inﬂuencedby immune responses at themucosal surfaces of
the respiratory tract, including the recruitment of innate immune cells,
and the activation of T cells and antibody responses (Murphy, 1994;
Virgin, 2007; Woodland and Randall, 2004). As such, there is intense
interest in developing vaccination strategies and viral vectors that
promote strong and long lasting protective immune responses against
viral respiratory tract pathogens. This is particularly important for viral
infections in different anatomical regions of the respiratory tract, since
the mechanisms controlling immunity in these airway compartments
can differ signiﬁcantly (Woodland and Randall, 2004). The overall goal
of theworkdescribedherewas todetermine the capacity of viral vectorsbased on parainﬂuenza virus 5 (PIV5) to elicit protection against lethal
respiratory tract infection by vaccinia virus (VACV).
Poxviruses such variola virus, the causative agent of smallpox, highly
fatalmonkey poxvirus, and VACV can establish lethal infections through
the respiratory tract (e.g., Buller and Palumbo, 1991; Kaufman et al.,
2008). While a live attenuated form of VACV is currently used in the
United States as a licensed smallpox vaccine, a number of concerns have
been raiseddue to risk of adverse effects of this vaccine (e.g., Jacobs et al.,
2009). VACV also presents major challenges to the development of
alternative vaccination approaches that are based on puriﬁed VACV
proteins and heterologous vectors expressing VACV antigens (Moss,
2006). First, VACVexists in twomajor infectious forms: the extracellular
enveloped virion (EEV) and the intracellular mature virion (IMV).
Importantly, the VACV antigens that are critical for neutralization of
these two forms differ (Fogg et al., 2004; Hooper et al., 2000). For
example, L1R is amyristoylated transmembraneprotein in the IMV form
and is an important target for IMV neutralization (Aldaz-Carroll et al.,
2005b; Franke et al., 1990; Wolffe et al., 1995). B5R is a membrane-
anchoredVACVproteinwith anextracellular domain containing regions
that are related to some complement regulatory proteins (Engelstad et
al., 1992). Antibodies against B5R are important for neutralization of the
EEV form (Aldaz-Carroll et al., 2005a; Bell et al., 2004; Galmiche et al.,
1999). Because antibodies that neutralize the IMV do not neutralize the
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forms is necessary for maximum protection (Lustig et al., 2005).
A second challenge to development of vectors for immunization
against poxviruses is that while VACV is itself highly immunogenic,
the individual protein antigens themselves are poorly immunogenic
outside of the context of VACV infections. Vaccination with puriﬁed
VACV proteins or with DNA vaccines encoding VACV proteins requires
multiple immunizations for protective responses (e.g., Berhanu et al.,
2008; Fogg et al., 2004; Hooper et al., 2000, 2003). Finally, the VACV
antigens that are important for control of infections initiated through
the respiratory tract versus systemic routes (intravenous or intraper-
itoneal) can differ, and the immune mechanisms for protection from
these different routes of infection are not completely understood
(Belyakov et al., 2005; Kaufman et al., 2008).
Given the importance of developing safe and potent vaccination
approaches against respiratory tract pathogens, we have developed the
parainﬂuenza virus PIV5 as a vaccine vector (Arimilli et al., 2008;
Capraro et al., 2008; Parks and Alexander-Miller, 2002). Our previous
work in bothmouse and ferretmodel systemshas shown that intranasal
(I.N.) delivery of PIV5 induces a potent antibody response, and that PIV5
is cleared from respiratory tissues by 7–9 days pi without evidence of
systemic infection (Capraro et al., 2008). Likewise, PIV5 vectors
expressing model antigens can elicit strong and long lasting T cell
responseswhich can display a high avidity phenotype (Gray et al., 2003;
Parks and Alexander-Miller, 2002). Importantly, vaccination of both
ferrets and mice with recombinant PIV5 vectors did not result in overt
pathology and there was no evidence of disease symptoms (Capraro et
al., 2008). These desirable properties raise the potential use of PIV5
vectors as vaccines against complex human pathogens which infect the
respiratory tract.
To test the hypothesis that PIV5-based vectors can elicit protective
immunity in the respiratory tract against VACV infection,we engineered
PIV5 vectors to express soluble forms of theVACV antigens L1R and B5R.
These PIV5-L1R/B5R vectors elicited long term (N1.5 years) protection
inmice from lethal I.N. VACV challenge,whichwas dependent on B cells
but not on CD8+ cells. These results highlight the potential for PIV5-
based vectors to provide protection against complex and highly lethal
human pathogens such as variola virus, but also raise the critical issue ofTK control 
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Fig. 1. Expression of L1R andB5R from recombinant PIV5 vectors. A) Schematic diagramof PIV5
sense RNA with the insertion site for L1R and B5R genes between HN and L. Black bar denote
expression. A549 cellswere infected at anMOI of 25with PIV5 vectors expressing TK, L1R or B5R
tagged proteins or for NP. 5× denotes the L1R portion of the gel exposed 5 times longer.how to generate strong immunity in airway compartments against
poorly immunogenic proteins such as those found with VACV.
Results
Construction of PIV5 vectors expressing VACV proteins L1R and B5R
The open reading frames for VACV L1R and B5R proteins were
modiﬁed by PCR to lack sequences coding for their transmembrane
domains and to encode a C-terminal HA tag for detection. These
modiﬁed L1R and B5R genes were individually inserted at the HN-L
junction encoded in the PIV5 infectious cDNA clone such that theywere
ﬂanked by PIV5 transcription signals (Fig. 1A). Viruses were recovered
fromcDNAclones andwere designated PIV5-L1R and PIV5-B5R. Growth
analyses of PIV5-L1R and PIV5-B5R did not show detectable differences
in tissue culture cells compared to WT PIV5 and expression of L1R and
B5R was stable during multiple passages (not shown).
As shown in Fig. 1B, western blot analysis of lysates from cells
infected with the PIV5-L1R and PIV5-B5R viruses showed HA-tagged
L1R and B5R expression consistent with predicted sizes of ~21 and
~35 kDa, respectively (Aldaz-Carroll et al., 2005a, 2005b). Similar to
previous data with VSV-based vectors (Braxton et al., 2010), B5R was
expressed at a somewhat higher level than L1R. Examination of
extracellular media (Fig. 1B, right panel) showed very efﬁcient time-
dependent released of B5R. By contrast,most of L1Rwas retainedwithin
the cell similar to that seen in the case of the control cytoplasmic protein
thymidine kinase (TK) expressed from a PIV5 vector (Parks et al., 2002).
Longer exposures showed a low level of extracellular L1R protein,
consistentwith secretion of this protein when linked to a signal peptide
(Shinoda et al., 2009).
Mice are protected from lethal VACV challenge after immunization with
PIV5 vectors expressing L1R and B5R
To determine if the PIV5 vectors conferred protection from lethal
VACV challenge, groups of 5 mice were immunized I.N. with PBS as a
control or by the I.N. or I.M. route with 106 PFU of both PIV5-L1R and
PIV5-B5R. Onday 28,micewere given a booster immunizationwith PBS14 18 24
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viruses used in this study. The genome structure of PIV5 is shown schematically as negative
s HA tag added to the L1R and B5R open reading frames. le, leader; tr, trailer. B) Protein
. At the indicated timepi,media and cell lysateswere analyzed bywesternblotting for HA-
99K.M. Clark et al. / Virology 419 (2011) 97–106I.N. or with the same dose of PIV5-L1R/B5R by either the I.N. or I.M.
routes. As a positive control, mice received a single sublethal I.N. dose of
VACV (102 PFU). Twenty onedays after the boost,micewere challenged
with VACV equivalent to 20 MTD50 by I.N. administration, and lethality
and weight were monitored daily.
As shown in Fig. 2A, positive control mice that received a sublethal
dose of VACV were protected from death following VACV challenge
(VACV control group). By contrast, mice that received PBS or only one
priming dose of the PIV5-L1R and -B5R vectors (PBS and single I.N.
and I.M. groups, Fig. 2A) succumbed to infection on day 7 or 8. Most
importantly,mice that received an I.N. prime followedby I.N. boostwith
the PIV5 vectors (I.N.–I.N. group) all survived lethal VACV infection.
Although mice immunized with PIV5-L1R/B5R did not succumb to
lethal VACV challenge, they did showed signs of VACV-induced disease.
This is evident in Fig. 2B which shows changes in body weight as a
percentage of initial weight before challenge. Control mice immunized
with a sublethal dose of VACV did not show changes in overall weight
(VACV control). By contrast, animals in all other groups showed a
substantial loss of weight that became evident at day 4 and maximal at
day 7 or 8 post VACV challenge. Mice receiving PBS, the single dose of
PIV5 vectors (I.N. and I.M. animals) or prime-boost by the I.M. route
(I.M.–I.M group) all lost substantial weight and either died or were
removed from the study when loss of weight reached more than 30%
of initial value. Importantly, mice given an I.N. prime and I.N. boost
with the PIV5-B5R and PIV5-L1R vectors (Fig. 2B, I.N.–I.N., openB
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Fig. 2. Mice vaccinated with PIV5-L1R and PIV5-B5R are protected from lethal VACV challen
combination of 106 PFU of PIV5-L1R plus PIV5-B5R through either the I.N or I.M route. On day
with the same dose of PIV5 vectors by the I.N. or I.M. route (I.N.–I.N. or I.M.–I.M groups). Cont
or prime-boost with PBS (open squares). Twenty one days after the boost, mice were challe
daily to determine survival (panel A) andweight loss (panel B) as a percent of initial body we
initial weight or development of severe disease characteristics that were indicative of termin
for I.N.–I.N. compared to I.M.–I.M. For panel B, * denotes pb0.001 for comparison of I.N.–I.N
boost I.N. doses of PBS (open triangle), a sublethal dose of VACV (VACV control, closed trian
combination (closed square) on the same days described for panels A and B. Mice were then
comparison of VACV, L1+B5, L1, and B5 groups compared to PBS control. For panel D, **; pb0
alone to PIV5-L1R alone or PIV5-L1R plus PIV5-B5R, respectively.triangles) also lost weight, but weight loss was delayed compared to
the PBS control and these I.N.–I.N. animals began to recover weight
by about day 8 post challenge.
To determine the ability of the individual PIV5 vectors to confer
protection, groups of mice were given prime-boost I.N. immunizations
with 106 PFU of PIV5-L1R alone, PIV5-B5R alone or a combination of the
two vectors. Mice were challenged with 20 MTD50 of VACV by I.N.
administration and lethality and weight were monitored daily. As
shown in Fig. 2C, VACV-immunized control mice (closed triangles)
survived VACV challenge, while all PBS-treated mice (open triangles)
succumbed to challenge by day 7 or day 8. Approximately 70–80% of
micegivena combinationof L1RplusB5Rvectors or given the L1Rvector
alone showedahigh level of protection fromdeath,whilemicegiven the
B5R vector alone showed a slightly lower level of protection (~40%)
from lethal VACV challenge. These results on survival from challenge
were supported by the results on weight loss shown in Fig. 2D, where
mice given either PIV5-L1Ronly or a combinationof PIV5-L1Rplus PIV5-
B5R lost the least amount of weight following lethal VACV challenge.
These results indicate thatwhile immunizationwith vectors expressing
B5R alone conferred at least some protection, the most effective
immunization included the PIV5 vector expressing L1R alone or in
combination with B5R.
To determine the degree of pathology following VACV challenge,
mice were immunized I.N. with PBS as a negative control, a sublethal
VACV dose as a positive control, or with 106 PFU of both PIV5-L1R andPe
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ge. Panels A and B) Groups of 5 mice each were immunized with PBS as a control or a
28, PIV5-vaccinated mice were boosted with either PBS as a control (I.N or I.M only) or
rol groups received either a sublethal level of VACV I.N. (closed diamond, VACV control)
nged with VACV equivalent to 20 MTD50 by I.N. administration. Mice were monitored
ight. Mice were euthanized at an experimental end point when they had a loss of 30% of
al stages of disease. For panel A, pb0.003 for comparison of I.N.–I.N. to I.N. only and also
. to VACV control. Panels C and D) Groups of 7 mice each were administered prime and
gle), or 106 PFU of PIV5-L1R and PIV5-B5R alone (open square and closed circle) or in
challenged with VACV and then monitored daily as in panel A. For panel C, pb0.02 for
.005; *, pb0.5when comparingweight loss between animals immunizedwith PIV5-B5R
100 K.M. Clark et al. / Virology 419 (2011) 97–106PIV5-B5R in a prime-boost protocol as described for Fig. 2. On day 28
post boost, micewere challengedwith VACV equivalent to 20MTD50 by
I.N. administration.Nasal tissue and the olfactory lobes of the brainwere
analyzed on day 7 post challenge by staining with hematoxylin and
eosin. Control mice immunized with a sublethal dose of VACV showed
intact nasal epithelium and clear nasal cavity (Fig. 3, panels A and B). By
contrast, PBS-treated mice showed inﬂammatory exudate (panel C)
ﬁlling much of the nasal cavity with a bilateral extension through the
cribiformplate into the adjacent olfactory lobes (white arrows, panel C).
There was extensive destruction of the nasal epithelium (black arrows,
panelD),with inﬂammatory cells beingpresent in submucosaand in the
nasal cavity. Formice immunizedwith the PIV5 vectors, VACV challenge
resulted in small amounts of exudates seen in the nasal cavity but there
was no extension into the brain region (Fig. 3, panel E). Higher
magniﬁcation showed only very low levels of inﬂammatory cells in the
exudates and onlyminimal disruption of the nasal epithelium (panel F).
PIV5 immunized animals showed no signiﬁcant lesions in lung tissue or
other organs including heart, liver, kidney and spleen (not shown).
Together, these data indicate that mice immunized with PIV5-L1R and
-B5R vectors show relatively low levels of pathology in the nasal tissue
at day 7post VACV challenge compared to control animals that succumb
to VACV infection.Recovery of weight loss in PIV5-L1R and -B5R immunized mice correlates
with clearance of challenge VACV from the lung tissue
To determine VACV load in lung tissue following challenge infection,
groups of 5 mice were immunized as described in the legend to Fig. 2
and then challenged 20MTD50 of VACV I.N. at 21 day after the boost. OnPBS C
2X
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C
D
Sublethal VACV Control 
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B
Fig. 3. Pathology in nasal tissue of vaccinated mice after lethal I.N. VACV challenge. Mice wer
both PIV5-L1R and PIV5-B5R as described in the legend to Fig. 2. Twenty one days after the b
were evaluated histologically. Pictures represent H&E staining of a cross section of nasal cavit
magniﬁcation in the 10× panels. Panels C and D from the PBS-treated control mice show ne
through the cribiform plate. White arrows (2×) indicate the disruption of integrity of cribifo
(10×) show areas of nasal epithelial ulceration. Panels E and F from mice immunized with
cavity and minimal tissue disruption. Panels A and B from the sublethal VACV control animdays 4, 8 and 12 post challenge, the titer of VACV in lung tissues was
determinedbyplaqueassay. As shown inFig. 4, noVACVwasdetected in
tissues fromcontrolmice given the sublethal dose of VACV, and thiswas
consistent with the lack of disease symptoms in these animals. PBS-
treated mice had high VACV titers in the lung tissue until day 8 when
they succumbed to infection (# in Fig. 4 denotes no animals survived).
Importantly, mice immunized with the PIV5-L1R and -B5R vectors had
VACV titers in lung tissues that were ~1 log lower than that seen in PBS
treated control mice on days 4 and 8. By day 12 after challenge, there
was no detectable VACV in lungs of mice immunized with PIV5 vectors
(* samples at D12, Fig. 4). Given the kinetics of weight loss after VACV
challenge of PIV5-immunizedmicewhichbegins by day4, reaches a low
point by day 8, and approaches normal levels by day 12, these results
suggest that recovery from disease symptoms and protection from
lethality correlate with clearance of VACV from lung tissue.Protection from lethal VACV challenge elicited by the PIV5-L1R and -B5R
vectors requires B cells but not CD8+ cells
Todeﬁne themechanismof protectionmediatedby the PIV5 vectors,
groups of 7 mice were immunized I.N. as described above in a prime-
boost protocol with PBS, sublethal VACV or a combination of both PIV5-
L1R and PIV5-B5R vectors. Eighteen days after boosting with PIV5
vectors, CD8+ cells were depleted frommice for 4 consecutive days by
daily administration of an anti-CD8 monoclonal antibody as detailed in
Materials andmethods. Flow cytometric analysis showed that anti-CD8
treatment resulted in a decrease of CD8+, CD3+ (CD8+ T cells) to less
than 1% of total splenic cells (data not shown). After I.N. challenge with
20 MTD50 of VACV, mice were monitored for lethality and diseaseontrol PIV5-L1R + PIV5-B5R 
E
F
e vaccinated I.N. with PBS, a sublethal dose of VACV, or prime and boost with 106 PFU of
oost, mice were challenged I.N. with 20 MTD50 of VACV. Seven d after challenge, tissues
ies and olfactory lobes of the brain. Boxes in 2× pictures outline the area shown in higher
crosis of the nasal epithelium with intense inﬂammation which extends into the brain
rm plate into the adjacent olfactory lobes and adjacent inﬂammation. The black arrows
the PIV5-L1R and PIV5-B5R show minimal ﬁbrinous inﬂammatory exudate in the nasal
al are within normal limits.
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Fig. 4. VACV load in lungs of mice vaccinated with PIV5-L1R and PIV5-B5R vectors.
Groups of 7 mice were vaccinated I.N. with PBS (black bars), a sublethal dose of VACV,
or prime and boost with 106 PFU of both PIV5-L1R and PIV5-B5R (hatched bars) as
described in the legend to Fig. 2. Twenty one days after the boost, mice were challenged
I.N. with 20 MTD50 of VACV and levels of VACV in lungs were determined by plaque
assay. Standard deviations are indicated by the error bars. *, no detectable virus; #, mice
succumbed to infection.
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Fig. 5. Protection from lethal VACV challenge elicited by PIV5-L1R and PIV5-B5R vectors
requires B cells but not CD8+ cells. A) Groups of 7 mice each were immunized by prime-
boost I.N.with PBS (closed triangles), a sublethal doseofVACV(closed squares), or 106 PFU
of PIV5-L1R and PIV5-B5R (open circles) as described in the legend to Fig. 2. CD8-positive
cells were depleted by daily administration of anti-CD8 antibody for 4 day as described in
Materials and methods. Mice were then challenged with 20 MTD50 of VACV by I.N.
administration, and then monitored daily to determine survival. * and ** denote pb0.001
and pb0.04 for comparison of PIV5 vaccinated and VV control vaccinated animals to PBS
vaccinated animals, respectively. B) Jh B cell-deﬁcient mice were vaccinated I.N. with as
described in the legend to Fig. 2. Twenty onedays after the boost,micewere challenged I.N.
with 20 MTD50 of VACV, and then monitored daily to determine survival. ^ denotes
pb0.022 for comparison of PIV5 vaccinated to VV control vaccinated animals.
101K.M. Clark et al. / Virology 419 (2011) 97–106symptoms. As shown in Fig. 5A, PBS-treated control mice succumbed to
lethal infection by days 8–10 (closed triangles), whereas all of the CD8-
depleted mice that had been immunized with PIV5-L1R/B5R vectors
were completely protected (open circles). Some CD8-depleted control
mice that had received a single sublethal dose of VACV also succumbed
to VACV challenge (closed squares), a ﬁnding that is consistent with
previous reports for a role of cellular immunity in the case of someVACV
infections (Belyakov et al., 2005; Wyatt et al., 2004). Although PIV5
immunizedmicewereprotected from lethality they still showeddisease
symptoms such as hunching and loss of weight (data not shown). For
PIV5-immunized mice, the magnitude of weight loss (~20–25%) and
kinetics of weight loss (maximal at day 8 post challenge) were very
similar to that seen without CD8 depletion (data not shown). Thus,
protection from VACV lethality induced by PIV5-L1R/B5R does not
depend on CD8+ cells.
To determine the role of B cells in protection elicited by the PIV5-
based vectors, Jh mice which lack B cells were immunized I.N. in a
prime-boost protocol as described above and then challenged I.N.
21 days after the boost with 20 MTD50 of VACV. Lethality and disease
symptoms were monitored daily. As shown in Fig. 5B, Jh mice
immunized with the PIV5-L1R/B5R vectors succumbed to VACV
challenge at a rate that was only slightly delayed compared to that
seen with the PBS-treated control mice. By contrast, control mice that
were immunized with a sublethal dose of VACVwere fully protected. Jh
mice that had been immunized with PBS or with the PIV5 vectors
showed the appearance of disease symptoms such as loss of weight and
hunching between day 4 and day 8 post VACV challenge (data not
shown). Taken together, these data indicate that protection from VACV
challenge that is elicited by the PIV5-L1R and PIV5-B5R vectors requires
B cells but not CD8+ cells.
Antibody responses to infection with PIV5-L1R and PIV5-B5R vectors
To assay anti-L1R and anti-B5R antibody responses, mice were
immunized I.N. with 106 PFU of either PIV5-L1R or PIV5-B5R and
serum was collected at day 14 and day 21. Mice were then boosted
with an equivalent amount of virus and serum was collected at day 4post boost. On day 10 post boost, mice were sacriﬁced and
bronchoalveolar lavage (BAL) ﬂuid was collected. Levels of serum
IgG speciﬁc for L1R, B5R and PIV5 were determined using previously
described ELISAs based on reactivity against puriﬁed L1R, B5R or PIV5
particles (Braxton et al., 2010; Capraro et al., 2008; Delaney et al.,
2010). Likewise, BAL ﬂuid was tested in ELISA for antigen-speciﬁc IgA
and IgG responses.
As shown in Fig. 6A, the PIV5-L1R and PIV5-B5R vectors elicited very
low serum IgG levels on day 14 that were speciﬁc for L1R (open
triangles) and B5R (closed squares). By 21 day post primary immuni-
zation, titers were slightly increased with a few animals failing to show
sero-convertion (Fig. 6A). By day 4 post boost however, nearly all
animals had seroconverted. This result contrastswith anti-L1R and anti-
B5R responses elicited by sublethal VACV infection which has been
shownpreviously in this sameELISA system to produce titers of 106 and
105, respectively (Braxton et al., 2010). Similarly, the PIV5 vectors
elicited anti-L1R and anti-B5R IgA and IgG titers in BAL that were at or
below the limit of detection in this ELISA (Fig. 6B). This low BAL Ig titer
against L1R and B5R contrasted with very strong anti-PIV5 IgA and IgG
titers in BAL (Fig. 6C) which averaged 103 and 104, respectively. These
results are similar to those published previously showing that VSV
vectors expressing L1R and B5R elicit low titers against these two VACV
proteins (Braxton et al., 2010).
VACV can exist in two major infectious forms: the extracellular
enveloped virion (EEV) and the intracellularmature virion (IMV)which
A B
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Fig. 6. PIV5-L1 and PIV5-B5 elicit neutralizing anti-L1 and anti-B5 antibodies. A–C) Groups of 5 mice were vaccinated I.N. with 106 PFU of either PIV5-L1 or PIV5-B5R and serum was
collected at days 14 and 21. Mice were boosted with an equivalent dose of the same virus and serum and BAL was collected on days 4 and 10 post boost, respectively. Samples were
analyzed by ELISA for anti-L1R (open triangles) or anti-B5R (closed boxes) IgG in serum (panel A). Alternatively, BAL was analyzed by ELISA for levels of IgA and IgG speciﬁc for L1R
or B5R (panel B) or PIV5 (panel C). In panel A, the dotted line at 103 indicates background level for nonspeciﬁc reaction. Numbers below the symbols indicate the number of animals
that did not sero-covert. Mean titers for a given set of animals are indicated by a horizontal bar. For panels A and B, titers were not statistically above that of negative controls. D and
E) Sera frommice immunized with a combination of PIV5-L1R/B5R vectors (panel D) or from control mice immunized with PBS (panel E) were analyzed in an in vitro neutralization
assay with 100 PFU of IMV VACV as described in Materials and methods. Serum frommice given a sublethal dose of VACV was analyzed as a positive control. Results are the mean of
sera from 5 mice with standard deviation shown by the bar. #, pb0.01 when comparing between the 100 PFU of VACV used as starting infectivity versus the PFU remaining when
treated with serum from immunized mice.
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Fig. 7. Mice immunized with PIV5-L1R and PIV5-B5R vectors show low neutralizing
antibody against the EEV form of VACV. Groups of 5 mice each were immunized by
prime-boost I.N. with PBS, a sublethal dose of VACV, PIV5 lacking an inserted gene or a
combination of 106 PFU of both PIV5-L1R plus PIV5-B5R as described in the legend to
Fig. 2. Sera collected at 14 day post boost were diluted 1:20, 1:40 or 1:80 and then
tested in a neutralization assay with 100 PFU of the EEV form of VACV. *, **, *** denote
pb0.14, pb0.0012 and pb0.0001 when compared to PBS control serum at 1:20 dilution.
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et al., 2000). To determine if the PIV5 vectors elicited antibodies capable
of neutralizing IMV form of VACV, sera from animals immunized with a
combination of PIV5-L1R and -B5R were analyzed in an in vitro
neutralization assay in which 100 PFU of the IMV VACV was incubated
with dilutions of serum before determining remaining infectivity by
plaque assay. As shown in Fig. 6D, sera from animals immunized with
PIV5-L1R and -B5R vectors contained a statistically signiﬁcant level of
neutralizing activity (estimated at 1:20 dilution to reduce infectivity by
50%). It is noteworthy that assaying thesedilutions of serum invitromay
give a biased view relative to the undiluted nature of blood. By contrast,
sera from control mice immunized with PBS showed no signiﬁcant
reduction in plaques (Fig. 6E). These data indicate that while the ELISA
shows low antibody titers against L1R and B5R in PIV5-immunized
animals, these sera are capable of neutralizing VACV in a functional
assay.
To determine if PIV5-based vectors elicited antibodies that were
also capable of neutralizing EEV VACV, sera from animals immunized
with a combination of PIV5-L1R and -B5R were analyzed in a plaque
reduction assay with the EEV form of VACV. As shown in Fig. 7, sera
from control mice immunizedwith PBS or with a control vector which
lacked a foreign gene (PIV5) showed no neutralization of EEV VACV,
whereas sera from control VACV immunized mice was effective in
neutralization. Importantly, sera frommice immunized with PIV5-L1R
and -B5R was capable of neutralizing the EEV form of VACV to a
slightly lower extent compared to neutralization of the IMV form
shown in Fig. 6. Thus, immunization with PIV5 vectors expressing B5R
and L1R elicits neutralizing antibodies capable of inactivating both the
IMV and EEV forms of VACV.PIV5-based vectors provide long term protection from VACV challenge
Theprotection fromVACVelicited inmiceby PIV5-L1R andPIV5-B5R
vectorswas long lasting. This is demonstrated in Fig. 8wheremicewere
given a prime-boost immunization I.N. with PBS as a control, a
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A, * denotes an animal that succumbed to an infection unrelated to VV challenge. # denotes pb0.003 in comparison of immunizedmice to PBS control. In panel B, * denotes pb0.01, when
comparing animals immunizedwith PIV5-L1R/B5R toVACVcontrol. Panels C andD) Serum frommice vaccinatedwith PIV5-L1Rand -B5R (panel C) orwith sublethal VACV (panel D)were
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103K.M. Clark et al. / Virology 419 (2011) 97–106combination of 106 PFU of PIV5-L1R and PIV5-B5R or a single sublethal
dose of VACV.Micewere then housed for 1.5 years before challenging
I.N. with 20 MTD50 of VACV. As shown in Fig. 8A, mice that had been
immunized with sublethal doses of VACV or with the PIV5 vectors
were protected from lethal challenge. One of these aged PIV5-
immunized mice died during this experiment due to necrosis
resulting from tail bleeding (star Fig. 8A), but this was not due to
lack of protection from I.N. challenge. As with newly immunized and
challenged animals, these mice that had been previously immunized
with PIV5-L1R and PIV5-B5R and challenged at later points showed a
loss of weight 8 day post challenge, but then rapidly regained weight
to nearly 90% of initial values (Fig. 8B).
Serum from mice that had been immunized with the PIV5 vectors
contained statistically signiﬁcant levels of neutralizing antibodies out
to 1.5 years after immunization. This is evident in Fig. 8C where a 1:25
dilution of serum from mice immunized with the PIV5-L1R and -B5R
vectors reduced IMV VACV infectivity by ~70% compared to the ~90%
seen with control sera from control mice that had received sublethal
VACV infection (Fig. 8D). Taken together, the above data indicate the
PIV5 vectors elicit protection from lethal I.N. VACV challenge that: 1)
requires a prime-boost combination by the I.N. route, 2) is seen with
either PIV5-L1R or PIV5-B5R, but is most effective when the L1R-
expressing vector is included, 3) reduces VACV induced pathology in
the nasal tissue, 4) requires B cells but is not affected by depletion of
CD8+ cells and 5) is long lasting in mice out to at least 1.5 years after
immunization.Discussion
The goal of the work described here was to test the ability of PIV5-
based vectors to elicit protective immunity against lethal I.N. VACV
challenge. The I.N. infection routewas chosenhere based on theneed for
new vaccines to protect against aerosolized VACV which may have
different requirements for protection from challenge by other routes
(Kaufman et al., 2008) and the assumption that parainﬂuenza viruses
would elicit the most robust responses by infection through the
respiratory route. Our results indicate that PIV5 vectors expressing the
VACV L1R and B5R proteins confer long lasting protective immunity
against lethal I.N. VACV challenge. Protection from VACV-mediated
lethality required a prime plus boost immunization protocol adminis-
tered by the I.N. route, depended on B cells but not CD8+ cells and was
capable of protectingmice for longer than 1.5 years after immunization.
While immunization with vectors expressing B5R alone conferred at
least some protection, the most effective immunization involved PIV5
expressing L1R alone or in combination with B5R. Taken together these
results support the further development of PIV5-based vectors for
immunization against highly pathogenic and complex human viruses
such as poxviruses.
Mice responded to ourPIV5vectors bygeneratinghighELISA titers of
antibodies to the PIV5 vector and but relatively low ELISA titers of
antibodies to VACV L1R and B5R proteins. We have previously shown
thatWT PIV5 elicits a very strong anti-PIV5 antibody response detected
in serum (Capraro et al., 2008) and here we extend this analysis to
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contrast, results from ELISA data showed that the serum antibody
responses to L1R and B5Rwere at low levels andwere not detectable in
BAL (Fig. 6). This is consistent with previouswork showing that the L1R
and B5R proteins are poorly immunogenic when expressed outside of
the context of the native VACV. This is also reﬂected in the need for
multiple vaccinations with pure L1R and B5R proteins to generate high
antibody titers that provide protection (Berhanu et al., 2008; Braxton et
al., 2010; Delaney et al., 2010; Fogg et al., 2004; Hooper et al., 2000; Xiao
et al., 2007). It is known that there is an initial innate response inmouse
lung to PIV5 infection. However, as we have shown that PIV5 is cleared
from the respiratory tract by 9 days after infection (Capraro et al., 2008),
it is unlikely that an innate response to the vector contributes
substantially to protection from lethal VACV infection. This is further
supported by the key ﬁndings that protection requires B cells and that
mice are protected up to 1½ years after immunization with the PIV5
vectors. Importantly however, the PIV5 vectors elicited protection in
mice that was dependent on B cells and generated functional anti-VACV
antibody titerswere easily detected during in vitro neutralization assays
(Figs. 5 and6). These data suggest that PIV5 vectors elicitmemoryB cells
that respond to secondary exposure during VACV challenge by
increasing levels of neutralizing anti-VACV antibodies. Alternatively,
protection from VACV challenge could involve antibody-mediated
cellular cytotoxicity (ADCC) or complement-mediated cell lysis, both
of which are dependent on antibodies to VACV proteins. The role of
complement inVACVprotectionhas been shownpreviously (Benhnia et
al., 2009), and is currently being tested in the context of PIV5-based
vectors.
In contrast to recent work with VSV-based vectors expressing L1R
and B5R where a single immunization provided protection (Braxton et
al., 2010), our PIV5 vector-mediated protection from lethal I.N. VACV
infection required a prime and a boost immunization administered by
the I.N. route. This may reﬂect a higher level or prolonged expression of
antigens in the airways of mice infected with VSV vectors compared to
PIV5 vectors. In viewof the ﬁnding that the anti-PIV5 antibody response
to primary I.N. infection of mice is very strong (titer of ~104, Capraro et
al., 2008), it is somewhat surprising that a boost with the same PIV5
vectors promoted protection from VACV challenge. This is particularly
true of anti-PIV5 titers in the BAL, whichwere very high for IgA.Work is
in progress to deﬁne the mechanism by which boosting with the PIV5
vectors inﬂuences protection from VACV challenge even in the face of a
strong response due to prior exposure to PIV5.
While the PIV5 vectors clearly protectedmice from succumbing to a
lethal VACV infection, immunized animals displayed some signs of
illness following VACV challenge. This was most notable in PIV5-
immunizedmice by the loss of weight starting at days 3–4, but this was
also evident by signs of illness such as hunching, rufﬂed fur,
conjunctivitis, labored breathing, lethargy and unresponsiveness to
stimulus (not shown). Importantly, the kinetics of appearance of illness
in PIV5-immunized mice was delayed and less severe compared to
control PBS-treated animals, and the PIV5-immunized animals showed
an improvement to near normal properties by day 12 post challenge.
Similar results have been shown for animals vaccinated with puriﬁed
VACV proteins (Delaney et al., 2010; Fogg et al., 2004) and with VSV-
based vectors expressing L1R and B5R (Braxton et al., 2010), where
immunized animals lost weight following VACV challenge even though
they were protected from lethality. The disease symptoms in PIV5-
immunized animals could reﬂect a delay in response of memory B cells
in PIV5 immunized animals to VACV antigens during the challenge.
Additional possibilities include a lower immune response to PIV5-based
vaccination due to the fact that PIV5 immunized animals are exposed to
only two of the multiple antigenic proteins that expressed during a
VACV infection (Berhanu et al., 2008; Fogg et al., 2004; Hooper et al.,
2000), or to alternative conformations of B5R and L1R when expressed
from PIV5 versus bone ﬁde VACV infection. In the latter case, we
engineered expression of soluble versions of L1R and B5R to enhancerelease from infected cells and possible uptake of secreted antigen.
However, as the immunogenicity of L1R is particularly sensitive to
conformational changes (Su et al., 2007), PIV5-expressed L1R may not
elicit strong antibody responses due to its expression as an HA-tagged
cytoplasmic protein.
There is intense interest in developing paramyxovirus-based
vectors for vaccination and therapeutic applications (Bukreyev et al.,
2006; Lamb and Parks, 2007; von Messling and Cattaneo, 2004), and
PIV5-based vectors have attractive properties relative to other vectors
based on viruses that are associated with human diseases. These
desirable PIV5 properties including infections are largely noncyto-
pathic in most cell types, and that PIV5 is not associated with any
disease in humans (Goswami et al., 1984). In ferrets and mice, PIV5
stimulates strong antibody and T cell responses, is cleared from
respiratory tissues by 7–9 days pi without evidence of systemic
infection (Capraro et al., 2008) and induces no overt pathology. As
discussed previously (Capraro et al., 2008), the ferret model may be a
more appropriate system for analysis of features of the PIV5 vectors,
since the mouse is not a good predictor of viral permissiveness/
tropism in humans. PIV5 can elicit strong systemic mucosal IgG and
IgA responses, even when delivered by different routes. PIV5 is grown
to very high titers (N1010 PFU/ml) in Vero cells, an approved cell line
for vaccine work. Finally, anti-PIV5 sero-prevalence can be relatively
low in many human populations (Hsiung, 1972; Johnson et al., 2008).
A PIV5 vector was shown to elicit protective immunity in mice against
inﬂuenza virus (Tompkins et al., 2007), although the mechanism of
protection in that study was not addressed.
There have been previous reports of PIV5 association with human
diseases, including Multiple Sclerosis (Goswami et al., 1984). At the
time, these were attractive associations, largely due to PIV5's property
of readily establishing persistent infections of cells with low levels of
pathology (Choppin, 1964). Importantly, all of these claims have been
disproven (McLean and Thompson, 1989) and it is currently thought
that PIV5 is not associatedwith any human disease. PIV5 variants have
been isolated from samples from human patients (Chatziandreou et
al., 2004). The divergence of sequence between these PIV5 isolates
indicates that these are not a common lab contaminant, but represent
bone ﬁde human infections. PIV5 does not establish persistent
infections in mice or ferrets and viral load appears to be restricted
to the respiratory tract (Capraro et al., 2008). Whether PIV5
establishes persistent infections in humans is not known.
Our work raises the important question of how virus-based vectors
could be improved upon in order to generate a more complete
protective immunity in different compartments of the respiratory
tract and reduce disease symptoms. We have previously shown that
engineered expression of the TLR5 agonist ﬂagellin enhanced the ability
of PIV5 to stimulate human dendritic cells and T cells (Arimilli et al.,
2008). Likewise, we have shown that PIV5 vectors based on RNA
synthesis mutants are potent activators of innate and adaptive
immunity (Capraro et al., 2008; Manuse and Parks, 2009). These results
with PIV5 variants support the general hypothesis that paramyxovirus
vectors can be designed to express a target antigen alongwith immuno-
modulatory factors that elicit a broader response to protect against both
lethality as well as reduce disease symptoms.
Materials and methods
Cells and viruses
The genes for VACV L1R and B5R have been described previously
(Aldaz-Carroll et al., 2005a, 2005b). The L1R and B5R open reading
frames were modiﬁed by PCR to encode a C-terminal HA tag, and then
inserted into the PIV5 cDNA encoding the intergenic region at the HN–L
junction. As described previously (He et al., 1997; Parks et al., 2002), the
new genes were ﬂanked by PIV5 transcription signals derived from the
NP–P gene junction and were fully functional in directing transcription
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the cloning steps are available on request. Recombinant viruses
individually expressing L1R and B5R were recovered as described
previously (Parks et al., 2002) from cDNA plasmids kindly provided by
Robert Lamb (Northwestern University) and Biao He (University of
Georgia). The TK-expressing PIV5 has been described (Parks et al.,
2002). For in vivo experiments, viruses were concentrated by
centrifugation through a glycerol cushion (5 h; 25,000 RPM; SW28
rotor), and virus pellets were resuspended in a small volume of DMEM
containing 0.75% BSA.
The IMV form of the Western Reserve (WR) strain of VACV was
prepared and puriﬁed as described by Delaney et al. (2010). The EEV
form of VACV was prepared exactly as described by Benhnia et al.
(2009) and was stored at 4 °C prior to use in assays. Neutralization
assays were carried out as described previously (Johnson et al., 2008).
Brieﬂy, 100 PFU of VACV were treated at 37 °C with varying
concentrations of immune or control serum for 1 h. All sera were
heat inactivated as described previously (Johnson et al., 2008). After
incubation, viral titers were determined by plaque assays on CV-1
cells. Results were the average of six reactions, with the signiﬁcance of
data points calculated using the student's t-test.
Immunization of mice and VACV challenge
All research performed on mice in this study complied with federal
and institutional guidelines set forth byWake Forest University Animal
Care and Use Committee. Female BALB/c mice (5–8 weeks of age) were
purchased from Charles River. Jh B cell-deﬁcient mice were of BALB/c
origin.Micewere anesthetizedwith avertin and immunized intranasally
(I.N.) as previously described (Capraro et al., 2008; Gray et al., 2003)
with 106 PFU of puriﬁed PIV5 vector in 20 μl of PBS. Control animals
were given a sublethal dose of 0.1 Median Tolerated Dose (MTD50) of
VACV (100 PFU) by I.N. administration in 10 μl of PBS. As the Wake
Forest University ACUC does not allow death as an endpoint, we used
MTD50 to denote a dose where 50% of the animals show signs of illness
(e.g. loss of weight to 70% of initial) that are signiﬁcant enough to
warrant euthanasia. Thus, 50% of the animals tolerate this dose of virus.
In prime-boost protocols, micewere given a second immunizationwith
106 PFU of virus at the indicated days post primary immunization.
In challenge experiments, mice were anesthetized with avertin and
infected I.N. with 1.7×106 PFU of VACV in 10 μl of PBS, which was
equivalent to 20 times the MTD50. Mice were monitored and weighed
daily to assess illness.Mice losing30%orgreater of their initialweight, or
exhibiting severe disease signs indicative of impending death, were
euthanized as required by IACUC guidelines of Wake Forest University
Health Sciences. At the indicated days pi, mice were sacriﬁced, and the
lungs were harvested by dissection, snap-frozen and stored at−80 °C.
Tissues were homogenized using a PowerGen 700 tissue homogenizer
(Fisher Scientiﬁc) followed by clariﬁcation of tissue debris at 450 g for
10 min asdescribedpreviously (Capraro et al., 2008), andused inplaque
assays as described above. Statistics for weight loss and survival were
calculated as student's t test and Log-Rank, respectively.
Depletion of CD8+ cells from mice
Depletion of CD8+ cells was carried out as described previously
(Braxton et al., 2010; Delaney et al., 2010). Brieﬂy, to purify anti-CD8
antibodies clone 2.43 hybridoma cells were grown to conﬂuency. Cells
were pelleted by centrifugation, and the media was ﬁltered and
concentrated. The concentrated media was dialyzed into 20 mM
sodium phosphate binding buffer and the antibody was puriﬁed using
the Akta chromatography system, following elution with a 100 mM
glycine elution buffer solution. Antibody was dialyzed in PBS and
concentration was determined by BCA. To deplete CD8+ cells, mice
were injected intraperitoneally for 4 consecutive days with 0.5 mg of
anti-CD8 antibody in a total volume of 0.5 ml PBS. As a control, somemice received an intraperitoneal injection of PBS. CD8 depletion was
conﬁrmed by ﬂow cytometry, with depletion resulting in a loss of
CD8+ and CD3+ cells (CD8+ T cells) to below 1% of total splenic cells.
ELISA and Western blotting
At the indicated days pi, mice were bled from the tail vein, and
blood was allowed to clot overnight at 4 °C before clariﬁcation by
centrifugation. ELISAs were carried out as described previously for
PIV5-speciﬁc antibodies (Capraro et al., 2008) or for L1R and B5R
(Braxton et al., 2010; Delaney et al., 2010). Proteins used in the ELISA
were baculovirus-derived recombinant histidine-tagged B5R and L1R
proteins generated in cultures of Sf9 cells and puriﬁed by metal
afﬁnity resin as described previously (Delaney et al., 2010).
For Western blotting, 6-well dishes of cells were infected as
described in the ﬁgure legends. At each time point, mediawas collected,
concentrated by TCA precipitation, and resuspended in 1% SDS. Cells
were washed with PBS and lysed in 1% SDS. Protein concentration was
determined by BCA assay (Pierce Chemicals). For each timepoint, the
entire media sample and 2 μg of cell lysate was analyzed by gel
electrophoresis under reducing conditions. Typically recovery of cell
lysate was ~500–700 μg of protein. Thus, 2 μg of protein analyzed
represented 0.3%–0.4% of the total intracellular sample. Western
blotting was carried out with rabbit antiserum speciﬁc for the PIV5 NP
protein or with a rat monoclonal antibody speciﬁc for the HA tag
contained on the L1R and B5R proteins (Roche Inc). Blots were
visualized by horseradish peroxidase-conjugated secondary antibodies
and enhanced chemiluminescence (Pierce Chemicals).
Pathology
The heads of the mice were removed and preserved whole in 10%
neutral buffered formalin for at least 24 h, and then decalciﬁed in
Decalciﬁer-2 (Polysciences) for 6–8 h before cross sections were made
through the noses at the level of the olfactory lobes of the brains. The
tissues were returned to formalin, embedded in parafﬁn, processed
routinely for histology, cut at 6 μm, and stained with hematoxylin and
eosin (H and E). The sections were examined by a board certiﬁed
veterinary pathologist and are representative of two experiments.
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